List view / Grid view
The only monoclonal antibody approved for passive immunisation to protect…
The only monoclonal antibody approved for passive immunisation to protect infants in their first RSV season has been approved by the US Food and Drug Administration (FDA).
Evusheld becomes first and only long-acting antibody combination available for…
Evusheld becomes first and only long-acting antibody combination available for both prevention and treatment of COVID-19 in Europe.
AstraZeneca has entered into a licence agreement with RQ Biotechnology…
AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2.
